Ubs Group Ag Ambrx Biopharma Inc. Call Options Transaction History

Ubs Group Ag

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q2 2023 Aug 11, 2023	SELL	$7.66 - $16.46 $792,044 - $1.7 Million	-103,400 Reduced 52.01%	95,400 $1.57 Million
Q1 2023 May 12, 2023	BUY	$1.46 - $12.54 $290,248 - $2.49 Million	198,800 New	198,800 $1.77 Million

31.2K

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.